文献速递甲状腺疾病

定义放射性碘难治性分化型甲状腺癌:SELECT试验中仑伐替尼按放射性碘难治标准分层的疗效与安全性

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
PubMed 文献 · Thyroid · 2017-08-14

SELECT试验亚组分析按三种放射性碘难治性分化型甲状腺癌(RR-DTC)标准分层,比较仑伐替尼与安慰剂的疗效与安全性。392例患者中,仑伐替尼在所有标准组均改善中位无进展生存期,客观缓解率56.0%-71.8%,不良事件相似。结论认为不同RR-DTC定义可能同等有效。

要点

  • 仑伐替尼在三种RR-DTC标准组均较安慰剂延长中位PFS。
  • 无RAI摄取组客观缓解率71.8%,进展但RAI亲和组60.0%,广泛RAI暴露组56.0%。
  • 仑伐替尼相关不良事件在各标准组间相似。

核心结论

  • 无论采用何种RR-DTC标准,仑伐替尼治疗的疗效和安全性特征相当,可能因满足各标准的患者间存在大量重叠。
  • 不同RR-DTC定义可能同等有效,因仑伐替尼和安慰剂组在各标准组间PFS结果相似。

研究设计与样本

  • SELECT为3期试验,入组可测量RR-DTC且研究入组前≤13个月有影像学疾病进展证据的患者,按2:1随机接受仑伐替尼(24 mg/天;28天周期)或安慰剂。
  • 本分析按RR-DTC入选标准分层:无RAI摄取、RAI治疗时具亲和性但治疗后12个月内进展、累积RAI暴露>600 mCi。
  • 共392例患者(仑伐替尼261例;安慰剂131例),所有患者均以疾病进展为SELECT入组标准。

主要发现

  • 275例满足无RAI摄取标准,235例满足RAI亲和但进展标准,73例满足广泛RAI暴露标准;167例(42.6%)满足超过一条标准。
  • 无RAI摄取组中位PFS:仑伐替尼不可量化(CI 14.8-不可量化)vs 安慰剂3.7个月(CI 2.5-5.3)。
  • RAI亲和但进展组中位PFS:仑伐替尼16.5个月(CI 12.8-不可量化)vs 安慰剂3.7个月(CI 1.9-5.4)。
  • 广泛RAI暴露组中位PFS:仑伐替尼18.7个月(CI 10.7-不可量化)vs 安慰剂3.6个月(CI 1.9-5.5)。
  • 客观缓解率分别为无RAI摄取组71.8%、RAI亲和但进展组60.0%、广泛RAI暴露组56.0%;仑伐替尼相关不良事件各组相似。

关键数值与推荐

  • SELECT总人群中仑伐替尼较安慰剂显著延长PFS:HR 0.21(99% CI 0.14-0.31),p < 0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While there is a clear consensus for defining radioiodine-refractory differentiated thyroid cancer (RR-DTC), it is unknown whether these criteria are equally valid for determining when radioiodine (RAI) therapy is no longer beneficial and systemic treatment should be considered. Lenvatinib, a multikinase inhibitor, significantly prolonged progression-free survival (PFS) compared to placebo in a Phase 3 trial in RR-DTC (SELECT; hazard ratio [HR]: 0.21 [99% confidence interval (CI) 0.14-0.31]; p < 0.001). This sub-analysis compared clinical outcomes of lenvatinib-treated patients in SELECT stratified by RR-DTC inclusion criteria. METHODS: In SELECT, patients with measurable RR-DTC and radiologic evidence of disease progression ≤13 months prior to study entry were randomized 2:1 to lenvatinib (24 mg/day; 28-day cycle) or placebo. In this analysis, patients were stratified based on the following RR-DTC inclusion criteria: no RAI uptake, disease progression within 12 months of RAI therapy despite RAI avidity at the time of treatment, and extensive (>600 mCi) cumulative RAI exposure. All had disease progression as an inclusion criterion for SELECT. RESULTS: Of 392 patients (261 lenvatinib; 131 placebo) enrolled, 275, 235, and 73 patients met the inclusion criteria for no RAI uptake, disease progression despite RAI avidity, and extensive RAI exposure, respectively. There was significant overlap between the patient groups, with 167 (42.6%) patients meeting more than one inclusion criterion. Lenvatinib improved median PFS compared to placebo in all groups ("no RAI uptake": lenvatinib not quantifiable [NQ; CI 14.8-NQ] vs. placebo, 3.7 months [CI 2.5-5.3]; "disease progression despite RAI avidity": lenvatinib 16.5 months [CI 12.8-NQ] vs. placebo, 3.7 months [CI 1.9-5.4]; "extensive RAI exposure": lenvatinib 18.7 months [CI 10.7-NQ] vs. placebo, 3.6 months [CI 1.9-5.5]). Objective response rates were 71.8%, 60.0%, and 56.0% for patients with no RAI uptake, disease progression despite RAI avidity, and extensive RAI exposure, respectively. Lenvatinib-related adverse events were similar across groups. CONCLUSIONS: Comparable efficacy and safety profiles were observed in lenvatinib-treated patients regardless of RR-DTC criteria, possibly because of a large overlap among patients fulfilling each criterion. However, differing definitions for RR-DTC may be equally valid because both lenvatinib and placebo arms exhibited similar PFS outcomes across groups.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kiyota N, Robinson B, Shah M, et al. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Thyroid. 2017. PMID: 28665259. doi:10.1089/thy.2016.0549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。